(PharmaNewsWire.Com, July 04, 2017 ) The Europe Leukemia Therapeutics market has been estimated at USD 1.51 Billion in 2016 and is projected to reach USD 2.26 Billion by 2021, at a CAGR of 8.4% during the forecast period from 2016 to 2021. Leukemia is commonly caused due to the high exposure to radiations, unhealthy lifestyle, genetic factors, and environmental conditions. Leukemia cases are more common in adults and are observed to progress with aging. It can be identified by the spread of the diseases and by the type of the blood cell that is affected.
The market for Leukemia Therapeutics in Europe is propelling mainly due to factors like increased innovation and R&D in the oncology sectors and growing number of biotechnology firms. But due to factors like high cost of drugs and treatments along with large number of entry-to-market barriers, the market growth is feared to diminish.
Europe market for Leukemia Therapeutics is segmented based on disease condition, diagnosis, treatments and drugs. By disease condition, the market is further sub-segmented into chronic lymphatic leukemia, acute lymphatic leukemia, chronic myeloid leukemia and acute myeloid leukemia. By diagnosis, the market is further sub-segmented into CT scan, biopsy and MRI. By treatments, the market is further sub-segmented into chemotherapy, radiation therapy, immunotherapy, surgery, targeted therapy, bone marrow transplant and stem cell therapy. By drugs, the market is further sub-segmented into Gleevec, Sapacitabine, GA101, Vasaroxine, Tosedosat. By disease condition, chronic myeloid leukemia dominated the overall therapeutic market owing to high prevalence rate. Stem cell therapy and bone marrow transplant are the emerging trends in leukemia therapeutic market. Gleevec was the one of the major market growth contributors, in the drugs category.
Geographically, Europe market for Leukemia Therapeutics is segmented into U.K., France, Spain, Germany, and Italy. Europe holds the second largest share in global market. A number of factors such as growing awareness of leukemia screening programs, and government support are paving the way for companies to penetrate into European Leukemia Therapeutics market.
F.Hoffmann-La Roche Ltd, GlaxoSmithKline Pharmaceuticals Limited, Novartis International AG, Bristol-Myers Squibb , Eisai Co. Ltd, Biogen Idec , ERYtech Pharma , Celgene Corporation, Genmab A/S, Cephalon Inc., Clavis Pharma, and Pfizer Inc. are the major players of Europe Leukemia Therapeutics market.
About Us: Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, we cater to the needs of both individual and corporate clients. Our analyst team comprises expert professionals in market research, who with their collective knowledge and skillset dedicatedly serve clients from various industries and regions.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
